secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001171843-23-002864
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Q1 rev down 47% to $6.7M; files patent suit vs Pfizer/BioNTech; AB-101 IND on hold
--------------------------------------------------------------------------------

- Q1 revenue $6.7M vs $12.6M YoY; net loss $16.3M ($0.10/shr) vs $15.8M ($0.11) YoY.
- Filed patent infringement lawsuit against Pfizer and BioNTech for COVID-19 LNP vaccine technology.
- FDA placed AB-101 (oral PD-L1) IND on clinical hold; Phase 1 not initiated, no patients dosed.
- Cash $178.5M; burn guidance reduced to $90-95M from $95-100M; runway into Q1 2025.
- Dosed first subject in Phase 1 trial for AB-161 (oral RNA destabilizer); data expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323002864/0001171843-23-002864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323002864/f8k_050423.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer